Evidence map›Paper›PMID 40380211›Full record

ReviewWorld journal of surgical oncology2025

SDC1 is a critical transmembrane proteoglycan in breast cancer.

Yingying Mei, Lantao Zhao, Na Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yingying Mei *Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, No.59 Haier Road, Qingdao, 266035, China.
Lantao Zhao *Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Na ZhouPrecision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, No.59 Haier Road, Qingdao, 266035, China. zhouna@qdu.edu.cn.

Funding

the National Natural Science Foundation of China Grant No. 81702605；82272693
6 · The paper itself

Abstract

There has been an increasing incidence of breast cancer around the world in recent years. As a burgeoning model of diagnosis and treatment, precision medicine has become a new trend in breast cancer management. Dysregulated glycometabolism is well established as a tumor feature. SDC1 is a glycometabolism-related gene and participates in the progression, metastasis, resistance and recurrence of malignant tumors. SDC1 promotes the development of breast cancer by disturbing tumor stem cell phenotypes, the cell cycle and apoptosis, and then modulates macrophage migration, epithelial-mesenchymal transformation, angiogenesis and the tumor-bone microenvironment. We summarized the recent advances regarding the role of SDC1 in the mechanism driving the occurrence of breast cancer, and evaluated its potential therapeutic contributions.

Indexed as

Biomarkers, TumorBreast NeoplasmsSyndecan-1AnimalsApoptosisEpithelial-Mesenchymal TransitionFemaleHumansNeoplastic Stem CellsNeovascularization, PathologicPrognosisTumor MicroenvironmentBiomarkers, TumorSDC1 protein, humanSyndecan-1Breast cancerSDC1Targeted therapyTumor microenvironment

Identifiers

PMID40380211
PMCPMC12082863

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.